SAM
MACK

Silvercrest Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Silvercrest Asset Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,180
Closed -$198K – 572
2015
Q4 		$198K Buy
+3,180
New +$224K ﹤0.01% 539
2015
Q3 		– Sell
-3,687
Closed -$359K – 508
2015
Q2 		$359K Buy
+3,687
New +$351K ﹤0.01% 425

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Silvercrest Asset Management's MACK Position: Q1 2016 in Review

Silvercrest Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2016, closing a stake of 3,180 shares — an estimated $198K sold.

Silvercrest Asset Management first reported a position in MACK in Q2 2015 and held it in 2 quarters. The position peaked at $359K in Q2 2015. 139 funds tracked by Wall St. Rank hold MACK as of Q1 2016.

  • Silvercrest Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Silvercrest Asset Management sold 3,180 Merrimack Pharmaceuticals, Inc. shares in Q1 2016, an estimated $198K.
  • Silvercrest Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • Silvercrest Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $359K in Q2 2015.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2016.

Based on Silvercrest Asset Management's 13F filing for Q1 2016, filed 16 May 2016.